Access the full text.
Sign up today, get DeepDyve free for 14 days.
BC Song, DJ Suh, HC Lee (2000)
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in KoreaHepatology, 32
ML Funk, DM Rosenberg, AS Lok (2002)
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variantsJ Viral Hepat, 9
SH Ryu, YH Chung, MH Choi (2003)
Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospectivestudyJ Hepatol, 39
SJ Hadziyannis, NC Tassopoulos, EJ Heathcote (2005)
Long-term therapy with Adefovir Dipivoxil for HBeAg-Negative chronic hepatitis BN Engl J Med, 352
SJ Hadziyannis, GV Papatheodoridis, E Dimou, A Laras, C Papaioannou (2000)
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis BHepatology, 32
DD Richman (2000)
The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis BHepatology, 32
SK Fung, F Wong, M Hussain (2004)
Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis BJ Viral Hepat, 11
JW Shin, NH Park, JH Park (2005)
Efficacy of lamivudine re-treatment for relapsed patients after an initial lamivudine therapy in HBeAg-positive chronic hepatitis BJ Viral Hepat, 12
HC Lee, DJ Suh, SH Ryu (2003)
Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversionGut, 52
F Liu, L Wang, XY Li (2011)
Poor durability of lamivudine effectiveness despite stringent cessation criteria : A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patientsJ Gastroentol Hepatol, 26
YH Huang, JC Wu, TT Chang (2003)
Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in TaiwanJ Viral Hepat, 10
(2009)
EASL clinical practice guidelines: management of chronic hepatitis BJ Hepatol, 50
YF Liaw, N Leung, JH Kao (2008)
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatol Int, 2
M Lindh, AS Andersson, A Gusdal (1997)
Genotypes, nt1858 variants, and geographic origin of hepatitis B virus—large-scale analysis using a new genotyping methodJ Infect Dis, 175
L Wang, F Liu, YD Liu (2010)
Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patientsJ Viral Hepat, 17
Y Liang, J Jiang, M Su (2011)
Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapyAliment Pharmacol Ther, 34
CT Wai, AS Lok (2002)
Treatment of hepatitis BJ Gastroenterol, 37
SJ Hadziyannis (1995)
Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatmentViral Hepat Rev, 1
MR Brunetto, M Stemler, E Schodel (1989)
Identification of HBV variants which can not produce precore derived HBeAg and may be responsible for severe hepatitisItal J Gastroenterol, 21
G Zeng, Z Wang, S Wen (2005)
Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in ChinaJ Viral Hepat, 12
(2003)
International consensus conference on hepatitis B, September 14–16, 2002J Hepatol, 39
Adefovir is usually applied for therapy of chronic hepatitis B (CHB), but its effectiveness after cessation is still unknown. This study was to evaluate the effectiveness of adefovir treatment with strict cessation criteria in hepatitis B e antigen (HBeAg)-negative patients and to identify potentially important factors. One hundred forty–five HBeAg-negative CHB patients who had received adefovir treatment for at least 24 months and for whom serum hepatitis B virus (HBV) DNA had remained undetectable for at least 18 months before cessation were included. They were followed up monthly during the first four months and at 3-month or 6-month intervals thereafter. Patients with ≥10 4 copies of HBV DNA per mL were defined as relapsed. In total, 95 patients relapsed within the follow-up time, and more than 93% relapsed within 12 months after adefovir cessation. Cumulative relapse rates at months 6, 12, 24, 36, 48 and 60 were 53.8%, 61.4%, 65.5%, 65.5%, 65.5% and 65.5%, respectively. Age was the only factor associated with relapse, with lower relapse rates in younger patients shown by Cox regression analysis. HBsAg seroconversion occurred in 12 patients, and none of them relapsed during follow-up. The effectiveness of adefovir therapy does not persist in HBeAg-negative CHB patients, even when strict cessation criteria are applied, except for patients aged ≤ 25 years. HBsAg seroconversion is the ideal endpoint of adefovir treatment.
Archives of Virology – Springer Journals
Published: Feb 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.